These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 34556990)

  • 1. Is There a Difference in the Clinical Efficacy of Diosmin and Micronized Purified Flavonoid Fraction for the Treatment of Chronic Venous Disorders? Review of Available Evidence.
    Cazaubon M; Benigni JP; Steinbruch M; Jabbour V; Gouhier-Kodas C
    Vasc Health Risk Manag; 2021; 17():591-600. PubMed ID: 34556990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic potential of micronized purified flavonoid fraction (MPFF) of diosmin and hesperidin in treatment chronic venous disorder].
    Hnátek L
    Vnitr Lek; 2015 Sep; 61(9):807-14. PubMed ID: 26465280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials.
    Kakkos SK; Nicolaides AN
    Int Angiol; 2018 Apr; 37(2):143-154. PubMed ID: 29385792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diosmin/hesperidin: a cooperating tandem, or is diosmin crucial and hesperidin an inactive ingredient only?].
    Karetová D; Suchopár J; Bultas J
    Vnitr Lek; 2020; 66(2):97-103. PubMed ID: 32942884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations for the medical management of chronic venous disease: The role of Micronized Purified Flavanoid Fraction (MPFF).
    Bush R; Comerota A; Meissner M; Raffetto JD; Hahn SR; Freeman K
    Phlebology; 2017 Apr; 32(1_suppl):3-19. PubMed ID: 28211296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Micronized Purified Flavonoid Fraction (MPFF) for Patients Suffering from Chronic Venous Disease: A Review of New Evidence.
    Ulloa JH
    Adv Ther; 2019 Mar; 36(Suppl 1):20-25. PubMed ID: 30758743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Benefits of Micronized Purified Flavonoid Fraction (MPFF) Throughout the Progression of Chronic Venous Disease.
    Nicolaides AN
    Adv Ther; 2020 Feb; 37(Suppl 1):1-5. PubMed ID: 31970659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled studies of Daflon 500 mg in chronic venous insufficiency.
    Geroulakos G; Nicolaides AN
    Angiology; 1994 Jun; 45(6 Pt 2):549-53. PubMed ID: 8203786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VEIN STEP: A Prospective, Observational, International Study to Assess Effectiveness of Conservative Treatments in Chronic Venous Disease.
    Mezalek ZT; Feodor T; Chernukha L; Chen Z; Rueda A; Sánchez IE; Ochoa AJG; Chirol J; Blanc-Guillemaud V; Lohier-Durel C; Ulloa JH
    Adv Ther; 2023 Nov; 40(11):5016-5036. PubMed ID: 37728696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The drug therapy of chronic venous insufficiency (a trial of the clinical use of the preparation Detralex)].
    Iablokov EG; Bogachev VIu; Domoradskaia AI
    Ter Arkh; 1996; 68(10):80-1. PubMed ID: 9026954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy of micronized purified flavonoid fraction: an overview.
    Struckmann JR
    J Vasc Res; 1999; 36 Suppl 1():37-41. PubMed ID: 10474049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids.
    Lyseng-Williamson KA; Perry CM
    Drugs; 2003; 63(1):71-100. PubMed ID: 12487623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Edema as a measure for severity of chronic venous insufficiency and efficacy of its treatment].
    Sapelkin SV
    Angiol Sosud Khir; 2008; 14(3):79-81. PubMed ID: 19791434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advantage of a micronized flavonoidic fraction (Daflon 500 mg) in comparison with a nonmicronized diosmin.
    Amato C
    Angiology; 1994 Jun; 45(6 Pt 2):531-6. PubMed ID: 8203783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Micronized purified flavonoid fraction-based conservative treatment of chronic venous disease in a real-world setting.
    Bogachev V; Boldin B; Turkin P; Samenkov A; Dzhenina O
    Future Cardiol; 2022 Sep; 18(10):777-785. PubMed ID: 36004765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double blind study of the pharmacodynamic and clinical activities of 5682 SE in venous insufficiency. Advantages of the new micronized form.
    Cospite M; Dominici A
    Int Angiol; 1989; 8(4 Suppl):61-5. PubMed ID: 2698903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular Insights for the Appropriate Management of Chronic Venous Disease: A Narrative Review of Implications for the Use of Venoactive Drugs.
    Gianesini S; De Luca L; Feodor T; Taha W; Bozkurt K; Lurie F
    Adv Ther; 2023 Dec; 40(12):5137-5154. PubMed ID: 37768506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assEssment and quaLity of lIfe improvEment with micronized Flavonoids.
    Jantet G
    Angiology; 2002; 53(3):245-56. PubMed ID: 12025911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective Effects of Micronized Purified Flavonoid Fraction (MPFF) on a Novel Experimental Model of Chronic Venous Hypertension.
    das Graças C de Souza M; Cyrino FZ; de Carvalho JJ; Blanc-Guillemaud V; Bouskela E
    Eur J Vasc Endovasc Surg; 2018 May; 55(5):694-702. PubMed ID: 29588131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and security of Daflon 500 mg in venous insufficiency and in hemorrhoidal disease.
    Meyer OC
    Angiology; 1994 Jun; 45(6 Pt 2):579-84. PubMed ID: 8203791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.